Nektar Therapeutics | NKTR - 流动负债



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 13.04B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


流动负债 更改 日
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amgen USD 24.96B 534M 2026-03
Baxter International USD 3.69B 723M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cara Therapeutics USD 11.04M 2K 2025-12
Cipla INR 70.14B 7.16B 2026-03
Dr.Reddys Laboratories INR 167.47B 9.16B 2026-03
Eisai JPY 340.25B 47.42B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Takeda JPY 2.43T 180.65B 2026-03
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Xencor USD 73.46M 22.45M 2026-03